ARN-509丨CAS 956104-40-8

ARN-509 is primarily used in pharmaceutical research and oncology for the treatment of prostate cancer, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic prostate cancer in clinical studies. It acts by inhibiting androgen receptor signaling, which is a key driver of tumor growth in prostate cancer. In medicinal chemistry and drug development, ARN-509 serves as a lead compound for the design of next-generation androgen receptor inhibitors and selective antiandrogen therapies. It is also utilized in preclinical studies to investigate mechanisms of androgen resistance, evaluate combination therapies, and explore androgen receptor signaling pathways in cancer and other diseases driven by androgen receptor activity.

The benefits of ARN-509 include its high selectivity, potent androgen receptor inhibition, and favorable pharmacokinetic profile. Unlike traditional steroidal antiandrogens, it does not activate the androgen receptor, reducing the risk of agonistic effects that can promote tumor growth. It has strong oral bioavailability, long half-life, and good tissue penetration, which enhances efficacy in clinical and preclinical settings. ARN-509 also demonstrates efficacy in patients resistant to other antiandrogen therapies, offering a valuable option in the management of advanced prostate cancer. Its high specificity minimizes off-target effects, supporting a better safety profile compared to less selective antiandrogen agents.